Theodore Alan Huizenga Sells 967 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now directly owns 50,265 shares of the company's stock, valued at $2,116,156.50. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE traded down $1.40 during trading on Friday, reaching $38.62. The stock had a trading volume of 724,201 shares, compared to its average volume of 782,526. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The firm's fifty day moving average is $42.57 and its 200 day moving average is $48.72. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of -6.09 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the business. Algert Global LLC grew its position in shares of Ultragenyx Pharmaceutical by 46.9% during the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company's stock worth $4,105,000 after buying an additional 23,580 shares during the period. Bamco Inc. NY bought a new position in Ultragenyx Pharmaceutical during the third quarter worth $2,666,000. Principal Financial Group Inc. grew its holdings in Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock worth $4,802,000 after purchasing an additional 76,150 shares during the period. Cerity Partners LLC bought a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $1,773,000. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock valued at $928,000 after purchasing an additional 294 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on RARE shares. Wells Fargo & Company boosted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research note on Friday, December 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Piper Sandler raised their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, January 13th. Finally, Wedbush reissued a "neutral" rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $93.50.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.